CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 157 enrolled
Drug / intervention
A-101 Topical Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03210337
NCT03210337Phase 2Completed

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts

Aclaris Therapeutics, Inc.·interventional·Posted Jul 6, 2017·Updated May 1, 2019

In Brief

A Phase 2 clinical trial evaluating A-101 Topical Solution and A-101 Vehicle Solution for Common Wart. Completed, enrolled 157 participants across 17 sites.

Detailed Summary

The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Wart
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 6, 2017
Enrollment StartAug 1, 2017
Primary CompletionMar 16, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.0 years ago

Interventions

A-101 Topical Solutiondrug

A-101 Topical Solution

A-101 Vehicle Solutiondrug

A-101 Vehicle Solution